Harrow has closed its acquisition of Melt Pharmaceuticals, bringing a portfolio of non-opioid, non-intravenous sedation candidates built on Zydis oral dissolving tablet technology into its fold. The lead asset, MELT-300—a fixed-dose sublingual combination of midazolam 3 mg and ketamine 50 mg—has completed Phase 2 and Phase 3 studies under a Special Protocol Assessment and is being advanced toward an NDA submission targeted for the first half of 2027, with potential U.S. approval in 2028. Harrow plans a limited set of additional studies, full operational integration of Melt, and a commercial rollout that initially leverages its established ophthalmic customer base before expanding to broader outpatient settings.
Strategically, this is more than portfolio expansion. Harrow is attempting to convert a successful compounded product footprint into an FDA-approved franchise and to parlay an ophthalmology-centric commercial engine into the much larger procedural sedation market. The company’s compounded sublingual MKO Melt is already used by hundreds of U.S. ophthalmic institutions, offering a ready-made channel for launch. If MELT-300 can translate that real-world familiarity into labeled claims and scalable manufacturing, Harrow could reset the playbook for compounding-to-NDA transitions in procedure-driven care.
Timing and positioning matter. Payers and providers are under pressure to move procedures to lower-cost sites and standardize opioid-sparing pathways, while managing staffing shortages and IV access bottlenecks that constrain throughput. A needle-free, sublingual, non-opioid option that aims for rapid onset and predictable recovery squarely targets those operational pain points. For patients, the promise is simpler sedation and less exposure to opioids. For ambulatory surgery centers, ophthalmology suites, GI labs, and dental offices, the potential prize is workflow efficiency without the logistical overhead of IV access or opioid handling. That said, adoption will depend on clear evidence that sublingual sedation consistently matches or outperforms IV protocols on onset, depth of sedation, safety, recovery time, and turnover—and that economics work within bundled payments and facility fee structures.
Medical Affairs and market access will have heavy lifts. Converting clinical superiority versus midazolam alone into practice change requires comparative data against real-world standards that often pair benzodiazepines with opioids or propofol. Generating pragmatic evidence on time-to-ready, discharge readiness, adverse event rates, and patient-reported experience in ophthalmology, endoscopy, and office-based procedures will be pivotal for formulary inclusion and protocol updates. Controlled-substance logistics for midazolam and ketamine, site credentialing for moderate sedation, and alignment with specialty guidelines will influence uptake just as much as efficacy.
Competitive dynamics are shifting as well. If MELT-300 becomes the first FDA-approved non-opioid, non-IV sublingual sedation therapy in the U.S., it could pressure IV-centric regimens and raise the bar for other needle-free entrants. MELT-210, a sublingual midazolam-only candidate with Phase 2/3 experience, gives Harrow a second potential SKU and pricing ladder to segment use by procedure complexity. The success of this strategy may also catalyze more specialty pharma deals that bridge compounding experience, proprietary delivery platforms, and NDA-grade assets in procedure-heavy markets.
The immediate question for senior leaders is whether Harrow can compress the evidence-to-economics gap quickly enough to make an impact by 2028. If it can prove that sublingual, non-opioid sedation reliably improves patient flow and total cost of care across multiple sites of service, the center of gravity in procedural sedation could shift toward tablet-based, office-ready protocols—and competitors will have to decide whether to fast-follow or rethink their IV-first assumptions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
